Central Nervous System Lymphoma — Trials

Central Nervous System Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

214 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 81
Recruiting: 54
Ph III recruiting: 5
Growth YoY: —
Industry share: 16%
Top sponsor: National Cancer Institute (NCI)
Termination share: 26.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (15)

clinicaltrialsPublishedShowing 1–8 of 8 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03964090	Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)	active not recruiting	Phase 2	48	National Cancer Institute (NCI)NIH	1	Sep 4, 2026	clinicaltrials
NCT03277729	A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	active not recruiting	Phase 1 / Phase 2	53	Fred Hutchinson Cancer Center